drugset / Trial / NCT05238012
Compare the Impact of Xuezhikang and Atorvastatin on Glucose Metabolism in Dyslipidemia Patients With Prediabetes
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is a prospective, randomized, open-label, multi-center trial. The primary objective of the study is to assess whether XZK 1200mg/d, compared to atorvastatin 20mg/d, has a favorable impact on HbA1c levels at 24 weeks of treatment in dyslipidemia patients with prediabetes
Timeline
- Start
- 2022-08-02
- Primary completion
- 2024-04-02
- Completion
- 2024-04-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Atorvastatin | Small molecule | 20 mg | Oral |
| Subject | Xuezhikang | Traditional medicine (herbal / TCM) | 600 mg | Oral |